Boehringer to Expand Greek Production Site for New Medicines
German drugmaker Boehringer Ingelheim is investing €120 million in an upgrade and expansion of its facility in Koropi, Greece, that will increase the company's capacity to produce existing and new medicines. Main disease areas, Boehringer said, include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis.
According to Boehringer, the expansion will create 110 additional jobs and increase medicine exports from Greece, particularly of Jardiance, a medication used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market.
Putting innovative production technologies in place to support successful R&D is a key investment driver at Boehringer. In 2022, the company’s global expenditure in human pharma R&D amounted to €4.6 billion.
“We have been present in Greece since 1966, and have gradually expanded our operations in the country,” said Hubertus von Baumbach, chairman of the board of managing directors at Boehringer Ingelheim. “This expansion investment will bring some of our most innovative therapies to an increasing number of patients globally,” von Baumbach added.
Boehringer started the production facility in Koropi in 1975. In 2020, the company announced multi-year investments to expand the site and its production capacity. The Koropi plant is the only industrial facility of a multinational pharmaceutical company in Greece producing innovative medicines.
